A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Govindan R, Page N, Morgensztern D et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J. Clin. Oncol. 24(28), 4539–4544 (2006).
  MedlineGoogle Scholar
• 2. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N. Engl. J. Med. 359(13), 1367–80 (2008).
  Medline CASGoogle Scholar
• 3. Yang S, Zhang Z, Wang Q. Emerging therapies for small cell lung cancer. J. Hematol. Oncol. 12(1), 45 (2019).
  MedlineGoogle Scholar
• 4. Micke P, Faldum A, Metz T et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer – what limits limited disease? Lung Cancer. 37(3), 271–276 (2002).
  MedlineGoogle Scholar
• 5. Oronsky B, Reid TR, Oronsky A, Carter CA. What's new in SCLC? A review. Neoplasia. 19(10), 842–847 (2017).
  Medline CASGoogle Scholar
• 6. Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM. Unravelling the biology of SCLC: implications for therapy. Nat. Rev. Clin. Oncol. 14(9), 549–561 (2017).
  Medline CASGoogle Scholar
• 7. Früh M, De Ruysscher D, Popat S, Crinò L, Peters S, Felip E. Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29(Suppl. 4), iv192–iv237 (2013).
  Google Scholar
• 8. Jett JR, Schild SE, Kesler KA, Kalemkerian GP. Treatment of Small Cell Lung Cancer. Chest 143(5), e400S–e419S (2013).
  Medline CASGoogle Scholar
• 9. Ardizzoni A, Favaretto A, Boni L et al. Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis – a Forza Operativa Nazionale Italiana Carcinoma Polmonar. J. Clin. Oncol. 23(3), 569–575 (2005).
  Medline CASGoogle Scholar
• 10. Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: What we know, what we need to know and the path forward. Nat. Rev. Cancer. 17(12), 725–737 (2017).
  Medline CASGoogle Scholar
• 11. Stratigos M, Matikas A, Voutsina A, Mavroudis D, Georgoulias V. Targeting angiogenesis in small cell lung cancer. Transl. Lung Cancer Res. 5(4), 389–400 (2016).
  MedlineGoogle Scholar
• 12. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 480(7378), 480–489 (2011).
  Medline CASGoogle Scholar
• 13. Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann. Oncol. 27(8), 1492–1504 (2016).
  Medline CASGoogle Scholar
• 14. George J, Lim JS, Jang SJ et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 524(7563), 47–53 (2015). • The first comprehensive study of genomic profiles of small-cell lung cancer (SCLC), which highlighted several key biological processes in SCLC and showed the virtual absence of actionable targetable driver mutations.
  Medline CASGoogle Scholar
• 15. Hellmann MD, Callahan MK, Awad MM et al. Tumor mutational burden and efficacy of Nivolumab monotherapy and in combination with Ipilimumab in small-cell lung cancer. Cancer Cell 33(5), 853–861.e4 (2018).
  Medline CASGoogle Scholar
• 16. Alexandrov LB, Nik-Zainal S, Wedge DC et al. Signatures of mutational processes in human cancer. Nature. 500(7463), 415–421 (2013).
  Medline CASGoogle Scholar
• 17. Ready N, Farago AF, de Braud F et al. Third-line Nivolumab monotherapy in recurrent SCLC: CheckMate 032. J. Thorac. Oncol. 14(2), 237–244 (2019).
  Medline CASGoogle Scholar
• 18. Chung HC, Piha-Paul SA, Lopez-Martin J et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. J. Thorac. Oncol. 15(4), 618–627 (2020).
  Medline CASGoogle Scholar
• 19. Gelsomino F, Lamberti G, Parisi C et al. The evolving landscape of immunotherapy in small-cell lung cancer: a focus on predictive biomarkers. Cancer Treat. Rev. 79, 101887 (2019).
  Medline CASGoogle Scholar
• 20. Huang W, Chen J-J, Xing R, Zeng Y-C. Combination therapy: future directions of immunotherapy in small cell lung cancer. Transl. Oncol. 14(1), 100889 (2021).
  MedlineGoogle Scholar
• 21. Ricciuti B, Naqash AR, Naidoo J et al. Association between immune-related adverse events and clinical outcomes to programmed cell death protein 1/programmed death-ligand 1 blockade in SCLC. JTO Clin. Res. Reports 1(4), 100074 (2020).
  Google Scholar
• 22. Horn L, Mansfield AS, Szczęsna A et al. First-line Atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N. Engl. J. Med. 379(23), 2220–2229 (2018).
  Medline CASGoogle Scholar
• 23. Paz-Ares L, Dvorkin M, Chen Y-HHY et al. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394(10212), 1929–1939 (2019).
  Medline CASGoogle Scholar
• 24. Frampton JE. Atezolizumab: a review in extensive-stage SCLC. Drugs 80(15), 1587–1594 (2020).
  Medline CASGoogle Scholar
• 25. Liu SV, Reck M, Mansfield AS et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with Atezolizumab, Carboplatin, and Etoposide (IMpower133). J. Clin. Oncol. 39(6), 619–630 (2021). • Practice-changing phase III randomized controlled trial that set the new first-line standard treatment for patients with extended-stage small-cell lung cancer.
  Medline CASGoogle Scholar
• 26. Paz-Ares L, Dvorkin M, Chen Y et al. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394(10212), 1929–1939 (2019). • Practice-changing phase III randomized controlled trial that set the new first-line standard treatment for patients with ES-SCLC.
  Medline CASGoogle Scholar
• 27. Goldman JW, Dvorkin M, Chen Y et al. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 22(1), 51–65 (2021).
  Medline CASGoogle Scholar
• 28. Mansfield AS, Każarnowicz A, Karaseva N et al. Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial. Ann. Oncol. 31(2), 310–317 (2020).
  Medline CASGoogle Scholar
• 29. Goldman JW, Garassino MC, Chen Y et al. Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study. Lung Cancer 149, 46–52 (2020).
  MedlineGoogle Scholar
• 30. Rudin CM, Awad MM, Navarro A et al. Pembrolizumab or placebo plus Etoposide and Platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J. Clin. Oncol. 38(21), 2369–2379 (2020).
  Medline CASGoogle Scholar
• 31. Leal T, Wang Y, Dowlati A et al. Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161. J. Clin. Oncol. 38(Suppl. 15), 9000–9000 (2020).
  Google Scholar
• 32. Facchinetti F, Di Maio M, Tiseo M. Adding PD-1/PD-L1 inhibitors to chemotherapy for the first-line treatment of extensive stage small cell lung cancer (Sclc): A meta-analysis of randomized trials. Cancers (Basel). 12(9), 1–18 (2020).
  Google Scholar
• 33. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell 144(5), 646–674 (2011).
  Medline CASGoogle Scholar
• 34. Lucchi M, Mussi A, Fontanini G, Faviana P, Ribechini A, Angeletti CA. Small cell lung carcinoma (SCLC): the angiogenic phenomenon. Eur. J. CardioThoracic Surg. 21(6), 1105–1110 (2002).
  MedlineGoogle Scholar
• 35. Garcia J, Hurwitz HI, Sandler AB et al. Bevacizumab (Avastin^®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 86, 102017 (2020).
  Medline CASGoogle Scholar
• 36. Tiseo M, Boni L, Ambrosio F et al. Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer: treatment rationale and protocol design of the GOIRC-AIFA FARM6PMFJM trial. Clin. Lung Cancer 16(1), 67–70 (2015).
  Medline CASGoogle Scholar
• 37. Spigel DR, Townley PM, Waterhouse DM et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J. Clin. Oncol. 29(16), 2215–2222 (2011).
  Medline CASGoogle Scholar
• 38. Tiseo M, Boni L, Ambrosio F et al. Italian, multicenter, phase III, randomized study of Cisplatin plus Etoposide with or without Bevacizumab as first-line treatment in extensive-disease small-cell lung cancer: the GOIRC-AIFA FARM6PMFJM trial. J. Clin. Oncol. 35(12), 1281–1287 (2017).
  Medline CASGoogle Scholar
• 39. Wallin JJ, Bendell JC, Funke R et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat. Commun. 7(1), 12624 (2016).
  Medline CASGoogle Scholar
• 40. Ciciola P, Cascetta P, Bianco C, Formisano L, Bianco R. Combining immune checkpoint inhibitors with anti-angiogenic agents. J. Clin. Med. 9(3), 675 (2020). • This paper showed that the combination of anti-angiogenetic agents and immunocheckpoint inhibitors could lead to a synergic antitumor activity.
  CASGoogle Scholar
• 41. Lee WS, Yang H, Chon HJ, Kim C. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp. Mol. Med. 52(9), 1475–1485 (2020). •• This paper showed that the combination of anti-angiogenetic agents could enhance anti-cancer immunity.
  Medline CASGoogle Scholar
• 42. Meder L, Schuldt P, Thelen M et al. Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer. Cancer Res. 78(15), 4270–4281 (2018). •• Preclinical model that demonstrates a synergic anti-tumor effect of the combination of anti-angiogenetic agents and immunocheckpoint inhibitors.
  Medline CASGoogle Scholar
• 43. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity. 39(1), 74–88 (2013).
  Medline CASGoogle Scholar
• 44. Reck M, Mok TSK, Nishio M et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir. Med. 7(5), 387–401 (2019).
  Medline CASGoogle Scholar
• 45. Socinski MA, Jotte RM, Cappuzzo F et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378(24), 2288–2301 (2018).
  Medline CASGoogle Scholar
• 46. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45(2), 228–247 (2009).
  Medline CASGoogle Scholar
• 47. Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin. Cancer Res. 19(14), 3936–3943 (2013).
  Medline CASGoogle Scholar
• 48. Nishino M. Immune-related response evaluations during immune-checkpoint inhibitor therapy: Establishing a ‘common language’ for the new arena of cancer treatment. J. Immunother. Cancer 4(1), 4–7 (2016).
  MedlineGoogle Scholar
• 49. Lamberti G, Andrini E, Sisi M, Di Federico A, Ricciuti B. Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication. Futur. Oncol. 16(23), 1751–1766 (2020).
  CASGoogle Scholar
• 50. Thomas A, Vilimas R, Trindade C et al. Durvalumab in combination with Olaparib in patients with relapsed SCLC: results from a phase II study. J. Thorac. Oncol. 14(8), 1447–1457 (2019).
  Medline CASGoogle Scholar